January 18, 2023
Video
Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.
Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
Stephen J. Freedland, MD, presents the case of a 67-year-old man with metastatic prostate cancer and give his initial impression.
January 17, 2023
Article
In response to the findings, The American Cancer Society is launching IMPACT, an initiative aimed at reducing prostate cancer mortality.
“We don’t want to subject patients to a therapeutic strategy that they are unlikely to benefit from,” says Atish D. Choudhury, MD, PhD.
January 13, 2023
The environmental footprint of prostate MRI and prostate biopsy is similar to a round-trip flight from London to Paris, according to the authors.
January 12, 2023
In this interview, Arvin K. George, MD, gives an overview of the current state of focal therapy and also discusses 2 clinical trials evaluating new technologies in the space.
"Even though most of the end points had been negative and found no benefit, I think there are a couple of findings that we've learned in 2022 that surprised me," says Mark A. Moyad, MD, MPH.
"We are...entering a new era for patients with urologic malignancies. Furthermore, we are expanding our reach and influence in patient care designed to improve outcomes," writes Michael S. Cookson, MD, MMHC.
January 11, 2023
Slovin says what’s interesting about the CAR-T platform she’s been exploring is that “we see pretty exquisite sensitivity to the cancer cells.”
